Loading…
← CockpitCompetitor Analysis › IDYA IDEAYA Biosciences, Inc.Open in the cockpit ↗

IDEAYA Biosciences, Inc.IDYACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Precision-oncology biotech using synthetic-lethality targets; lead drug darovasertib treats uveal melanoma.

Momentum weak 20
Mkt cap
$2.56B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$36.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-135.7 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
97 days
23 Feb 2027
Close · USD$26.49
1D-3.3%
1W-19.0%
1M-25.1%
3M-32.3%
6M-10.7%
YTD-23.4%
1Y-20.6%
ATR %6.6%
Beta1.05
52w lowhigh37.9% off high

What IDEAYA Biosciences does

Precision-oncology biotech using synthetic-lethality targets; lead drug darovasertib treats uveal melanoma.

Has no approved product, so revenue is limited to payments from partners such as GSK, which works with it on its Pol theta programme; trials are funded by cash raised from selling shares. Darovasertib is a pill that blocks a protein driving uveal melanoma, a rare eye cancer.

Products and services

  • Darovasertib (uveal melanoma)
  • Synthetic-lethality pipeline (Pol theta, MTAP)

Where it sits in the supply chain

  • Biopharma R&D
  • Synthetic-lethality/precision oncology…
  • Partnered clinical development (GSK)

What could go right

  • Darovasertib approval pathway
  • GSK partnership milestones

What could go wrong

  • Binary trial-readout risk
  • Reliance on partner funding/decisions

Moat: none (IP / patents). Clinical-stage biotech; value depends on trial data and partner (GSK) milestone payments.

Headquarters: South San Francisco, California, US · Founded: 2015 · Employees: 145

Named competitors

IDEAYA Biosciences at a glance

Size IDEAYA Biosciences (IDYA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.56B, the 1630th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.49 on 18 Nov 2026.

Performance Over six months the shares fell 10.7%, against -8.4% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue fell 83.0% over the last twelve months (peer median +5.1%); the operating margin is -1,267.4% (peer median 11.3%).

Valuation It trades at 48.0× enterprise value to sales against a peer median of 4.2× (2nd most expensive of 20).

Capital Return on invested capital runs 135.7 points below its cost of capital (6.6% WACC).

Backlog Backlog (remaining performance obligations) was $140M at 30 Sep 2026, down 2% on a year earlier. Backlog detail →

Short interest Short interest is 8.5% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 90IDYA 90
Six months, rebased to 100: IDEAYA Biosciences against the median of its 20 peers (local-currency closes).

IDEAYA Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$36.5M$219M$7.00M$23.4M$50.9M
Revenue growth—+3,024%-70%-54%—
Gross profit$32.0M$214M$3.17M$19.4M$48.8M
EBITDA-$459M-$155M-$323M-$130M-$60.4M
Net income-$420M-$114M-$274M-$113M-$58.7M
Free cash flow-$350M-$73.5M-$251M-$118M-$90.6M
Capital expenditure$2.44M$2.37M$3.86M$2.37M$3.44M
Total debt$29.7M$27.9M$19.2M$2.87M$3.48M

Quarterly statements and history in the cockpit →

IDEAYA Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%600518301301BIOA-BALM300199PBH369621620013NAMS000250PRGORGC301080600380NEULANDLAB0867APLLTDIDYA6-month return →1-month return →
Up and to the right = strong over both horizons. IDEAYA Biosciences is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%0×20×40×60×600518301301BIOA-BALM30019936962162NAMS000250PRGO301080IDYARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IDEAYA Biosciences is the large dot.

IDEAYA Biosciences competitors and peer comparison

Head to head with its named competitors (IDYA vs GSK.L vs FHTX vs IMCR)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
IDEAYA Biosciences IDYA$2.56B-11%-83%-1,267%48.0×n/a
GSK GSK.L$97.9B-3%+4%25%2.8×-0.1%
Foghorn Therapeutics FHTXn/a-55%n/an/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR$1.44B-7%+13%-7%2.3×n/a
Tango Therapeutics TNGX$3.71B+4%-100%n/an/an/a

How IDEAYA Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IDEAYA Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureIDYAPeer medianRank in peer set
1-month return-25.1%-3.6%3rd lowest of 21
6-month return-10.7%-8.4%10th lowest of 21
Distance from 52-week high-37.9%-27.5%10th lowest of 21
Revenue growth (TTM)-83.0%+5.1%lowest of 20
Operating margin-1,267.4%11.3%lowest of 20
EV / Sales48.0×4.2×2nd most expensive of 20
ROIC minus cost of capital-135.7 pp-1.2 pplowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%48.0×n/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%3.3×n/an/a
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%4.2×3.4%+4.8%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%25.1×25.5%+100.1%
Almirall ALM.MCSpain$2.46B-13%+24%8%1.9×6.1%+6.5%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%12.9×37.4%+6.1%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%5.2×23.2%+14.0%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%3.8×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%13.6×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%16.8×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%2.0×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%67.0×n/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%11.8×n/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%1.3×14.1%+0.8%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%14.0×41.3%+27.7%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%1.6×-13.1%+2.4%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%1.5×-2.5%-5.8%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%11.9×n/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%1.8×1.1%+2.7%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%2.6×26.7%+6.5%

IDEAYA Biosciences backlog

IDEAYA Biosciences reported $140M of remaining performance obligations at 30 Sep 2026, down 2% from a year earlier and down 5% from the previous quarter. Book-to-bill last quarter: 0.29.

Questions

Who are IDEAYA Biosciences's main competitors?
Named competitors: GSK (GSK.L), Repare Therapeutics (private or unlisted), Foghorn Therapeutics (FHTX), Immunocore (IMCR), Tango Therapeutics (TNGX). The cockpit's measured peer set (industry) also includes Kangmei Pharmaceutical (600518.SS), Yili Chuanning Biotechnology (301301.SZ), BioArctic (BIOA-B.ST), Almirall (ALM.MC), Hybio Pharmaceutical (300199.SZ), Betta Pharmaceuticals (300558.SZ).
Is IDEAYA Biosciences expensive compared with its peers?
On ev / sales it trades at 48.0× against a peer median of 4.2×, 2nd most expensive of 20 in its peer set.
How has IDEAYA Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -10.7% against -8.4% for the median peer; over one year -20.6%.
What is IDEAYA Biosciences's backlog?
IDEAYA Biosciences's remaining performance obligations (contracted revenue not yet recognised) were $140M at 30 Sep 2026, -2% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.